Publications
Efficacy and Tolerability of a Low-Dose Continuous Regimen of Regorafenib in Refractory Synovial Sarcomas: A Single-Arm, Phase II Trial From India
Sanal Fernandes 1 , Sameer Rastogi 1 , Kanu Priya Bhatia 1 , Shamim A Shamim 2 , Adarsh Barwad 3 , Rambha Pandey 4 , Shivanand Gammanagatti 5 , Ekta Dhamija 5 Advanced synovial sarcomas are associated with poor outcomes and a lack of efficacious therapeutic agents. The aim of this study was to assess the efficacy and safety of a novel, low-dose, continuous schedule of regorafenib in these patients.
